Developer docs
API playgroundTry for free, no card

Search company profiles

Wondfo USA

Full company profile

uuid000nmk8

Namestring
Wondfo USA
Legal namestring
WONDFO USA CO., LTD.
Websiteurl
wondfousa.com
Company typeenum
Private
Founded yearint
2009
Descriptiontext

Wondfo USA Co. Ltd. is a privately held manufacturer of point-of-care diagnostic tests, founded in 2009 and headquartered in Bolingbrook, IL, with a research and production center in San Diego, CA and a dedicated Canadian distribution facility. The company sells lateral-flow immunochromatographic assays and one immunofluorescence instrument (PETlife Pro-DX) across four branded sub-portfolios: WELLlife (infectious disease, including FDA 510(k)-cleared and EUA-authorized COVID-19, Influenza A&B, and multiplex COVID/Flu tests, plus Strep A and iFOB colorectal screening), SAFElife (urine, oral-fluid, and hair toxicology plus fentanyl, xylazine, and benzodiazepine harm-reduction test strips), HORMONElife and BABYlife (pregnancy, ovulation, FSH, and PdG testing paired with a fertility-prediction mobile app), and PETlife (canine/feline progesterone, T4, and pancreatic lipase testing with a companion breeder app). Core technology is conventional rapid lateral-flow chemistry with sub-brand-specific assay formulations achieving claimed accuracies of >95% to >99% against gold-standard LC-MS/MS comparators; no AI-native capabilities are disclosed beyond simple probability modeling in the HORMONElife app.

Short descriptiontext

Wondfo USA manufactures point-of-care rapid diagnostic tests — including COVID-19/Flu A&B multiplex, toxicology, harm reduction, women's fertility, and veterinary assays — serving consumers, healthcare providers, employers, and veterinarians across the US and Canada.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersBolingbrook, United States
HQ citystring
Bolingbrook
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
point-of-care diagnostics, lateral flow assays, infectious disease testing, drug testing products, reproductive health tests
NAICS code1 code
  • In-Vitro Diagnostic Substance Manufacturing325413
SIC code1 code
  • In Vitro & In Vivo Diagnostic Substances2835
Product category
Point-of-Care Diagnostics
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model2 records
1Rapid Diagnostic Test Products
TypeOne Time License
Description

One-time purchase model for point-of-care diagnostic test kits across infectious disease, toxicology, women's health, and veterinary categories. Revenue from product sales through direct channels, distributors, and retail partners.

wondfousa.com
2Instrument/Analyzer Sales
TypeHardware Sales
Description

Sale of diagnostic instruments including PETlife Pro-DX Immunofluorescence Analyzer for veterinary diagnostics. No contract tie-in, pay-per-test model.

wondfousa.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels5 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Supply Chain, Personnel, Technology or R&D, Marketing or Sales, Operations
Pricing details1 tier
1Product pricing varies by product category and configuration
ModelUnit PricingBilling cadencePay-as-you-go
Notes

Pricing available through product inquiry forms and distributor relationships

wondfousa.com
GTM typeB2B and B2C
B2B and B2C
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 5 records shown
1WELLlife
Description

Rapid point-of-care and OTC testing products for infectious diseases including COVID-19, influenza, and iFOB tests for health providers and consumers.

wondfousa.com
+4 more records
Core offering1 text field

Wondfo USA manufactures and distributes rapid point-of-care diagnostic test kits and benchtop analyzers across four divisions: WELLlife (infectious disease such as COVID-19, influenza A&B, strep A, fecal occult blood), SAFElife (drugs of abuse screening in urine, oral fluid, hair, and surface samples), HORMONElife and BABYlife (women's reproductive health strips), and PETlife (veterinary diagnostics run on the Pro-DX immunofluorescence analyzer). The company sells through direct sales, authorized distributors, retailers, and a Canadian distribution center to both professional healthcare customers and at-home consumers.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • COVID-19 Antigen Test: Over 99% accuracy for negative tests, Over 84% accuracy for positive tests
+4 more records
Product overview1 text field

Wondfo USA is a leading manufacturer of point-of-care rapid diagnostic tests organized into four main product sub-brands: WELLlife (infectious disease testing), SAFElife (toxicology/drug testing), HORMONElife/BABYlife (women's health and fertility), and PETlife (veterinary diagnostics). The WELLlife portfolio includes FDA 510(k) cleared and EUA-authorized COVID-19/Influenza A&B multiplex tests, standalone COVID-19 antigen tests, Flu A&B tests, iFOB fecal occult blood tests for colorectal cancer screening, and Strep A tests. SAFElife offers comprehensive toxicology solutions including multi-drug urine test cups and dip cards, oral fluid tests for cotinine and alcohol, hair follicle tests for long-term drug detection (90 days), and harm reduction test strips for fentanyl, xylazine, and benzodiazepines in liquid/powder samples. HORMONElife and BABYlife provide pregnancy tests, ovulation predictor kits, FSH tests, and a companion mobile app with predictive analytics for fertility tracking. PETlife features a portable immunofluorescence analyzer (Pro-DX) for canine progesterone, T4 thyroid, and pancreatic lipase testing, paired with the Pup Planner mobile app for breeders.

Product and service19 records
1WELLlife COVID-19 Antigen Test
CategoryInfectious disease rapid antigen test
2WELLlife COVID-19 / Influenza A&B Antigen Test
CategoryMultiplex respiratory antigen test
3WELLlife Influenza A&B Test
CategoryInfectious disease rapid antigen test
4WELLlife iFOB Fecal Occult Blood Test
CategoryGI screening rapid test
5WELLlife Strep A Test
CategoryInfectious disease rapid antigen test
6SAFElife Multi-Drug Urine Test Cup
CategoryDrugs-of-abuse urine screening
7SAFElife T-Dip Multi-Drug Urine Dip Card
CategoryDrugs-of-abuse urine screening
8SAFElife Fentanyl Urine Test
CategoryDrugs-of-abuse urine screening
9SAFElife T-Swab Cotinine and Alcohol Oral Fluid Test
CategoryDrugs-of-abuse oral-fluid screening
10SAFElife Hair Processor and Multi-Panel Rapid Hair Test
CategoryDrugs-of-abuse hair screening
11SAFElife Fentanyl Liquid and Powder Test Strip
CategoryDrugs-of-abuse surface contamination test
12SAFElife Xylazine Liquid and Powder Test Strip
CategoryDrugs-of-abuse surface contamination test
13SAFElife Benzodiazepines Liquid and Powder Test
CategoryDrugs-of-abuse surface contamination test
14HORMONElife Pregnancy Test
CategoryReproductive health home test
15HORMONElife Ovulation Test Strip
CategoryReproductive health home test
16HORMONElife PdG Urine Test Strip
CategoryReproductive health home test
17HORMONElife Ultra Accurate FSH Test Strip
CategoryReproductive health home test
18BABYlife Pregnancy Test
CategoryReproductive health home test
19PETlife Pro-DX Immunofluorescence Analyzer
CategoryVeterinary diagnostic instrument
Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership4 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-05-16
Description

Collaboration with DCN Dx, a leading contract research organization for in vitro diagnostics, through the NIH Rapid Acceleration of Diagnostics (RADx) Tech program for the development of WELLlife COVID-19/Influenza A&B test. DCN Dx provides research and validation services ensuring highest quality, accuracy, and reliability.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-05-16
Description

NIH RADx Tech program supporting rapid development and validation of COVID-19/Influenza diagnostic tests. Provides funding, expertise, and validation infrastructure for accelerated FDA clearance.

Strategic tierMinorTypeOthers
Description

Market research firm providing industry analysis on pet at-home diagnostics market. Wondfo USA identified as one of 15-20 active players in market projected to reach USD 150.65 million by 2036.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Comparative evaluation partner for SAFElife Multi-Panel Rapid Hair Test. Omega Laboratories conducted independent validation comparing Wondfo's hair test against their gold standard LC-MS/MS methodology.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
1Abbott (Diagnostics)
TypeBroad incumbent
Description

Global diagnostics leader with BinaxNOW rapid COVID/Flu and Strep tests, plus broader IVD and lab-testing franchises. Competes with Wondfo across rapid respiratory testing categories but at materially greater scale and brand recognition.

TypeDirect peer
Description

Major US manufacturer of rapid IVD tests including COVID-19, Influenza A/B and Strep A assays used in both clinical point-of-care and OTC channels. Highly comparable product portfolio, channels, and regulatory posture to Wondfo's WELLlife line.

TypeDirect peer
Description

US-headquartered rapid diagnostic manufacturer with lateral-flow COVID, Flu, pregnancy, fertility and drug-of-abuse tests sold OTC and to clinical channels. Closely comparable product mix and channel strategy to Wondfo across all four sub-brands.

TypeDirect peer
Description

Canadian rapid IVD manufacturer with strong HIV, pregnancy, drug-of-abuse and infectious disease lateral-flow products. Direct peer in both product categories and North American distribution footprint overlapping with Wondfo's Canadian channel.

TypeBroad incumbent
Description

Operates the BD Veritor rapid-testing system for Flu, COVID and Strep A used in physician offices and urgent care, alongside women's health and drug-testing products. A broad incumbent overlapping directly with WELLlife and SAFElife.

TypeBroad incumbent
Description

Global leader in veterinary diagnostics with in-clinic analyzers and rapid test kits for companion and livestock animals. Overlaps with Wondfo's PETlife Pro-DX analyzer at a much larger installed base, particularly in fertility, thyroid and pancreatic testing.

TypeDirect peer
Description

Global leader in home pregnancy and ovulation testing under the Clearblue brand, with connected fertility tracking. Directly comparable to Wondfo's HORMONElife/BABYlife lines at a much larger consumer brand scale.

TypeDirect peer
Description

US-based drug-testing and toxicology product manufacturer offering urine drug test cups, dip cards, oral fluid and saliva-based tests. Direct overlap with Wondfo's SAFElife multi-drug, fentanyl and harm-reduction product lines.

TypeBroad incumbent
Description

Largest pure-play animal health company with diagnostics, vaccines, and point-of-care vet testing. Competes with Wondfo PETlife in the broader vet diagnostics market but offers a much wider portfolio beyond diagnostics.

TypeDirect peer
Description

Developer and manufacturer of rapid immunoassay tests for pregnancy, ovulation, drugs of abuse, infectious disease and cardiac markers. Closely comparable rapid-test product mix and lateral-flow technology base to Wondfo's HORMONElife, SAFElife and WELLlife lines.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability2 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles2 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance13 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Wondfo USA

Point-of-Care Diagnosticswondfousa.com

Wondfo USA manufactures point-of-care rapid diagnostic tests — including COVID-19/Flu A&B multiplex, toxicology, harm reduction, women's fertility, and veterinary assays — serving consumers, healthcare providers, employers, and veterinarians across the US and Canada.

What Wondfo USA does

Wondfo USA Co. Ltd. is a privately held manufacturer of point-of-care diagnostic tests, founded in 2009 and headquartered in Bolingbrook, IL, with a research and production center in San Diego, CA and a dedicated Canadian distribution facility. The company sells lateral-flow immunochromatographic assays and one immunofluorescence instrument (PETlife Pro-DX) across four branded sub-portfolios: WELLlife (infectious disease, including FDA 510(k)-cleared and EUA-authorized COVID-19, Influenza A&B, and multiplex COVID/Flu tests, plus Strep A and iFOB colorectal screening), SAFElife (urine, oral-fluid, and hair toxicology plus fentanyl, xylazine, and benzodiazepine harm-reduction test strips), HORMONElife and BABYlife (pregnancy, ovulation, FSH, and PdG testing paired with a fertility-prediction mobile app), and PETlife (canine/feline progesterone, T4, and pancreatic lipase testing with a companion breeder app). Core technology is conventional rapid lateral-flow chemistry with sub-brand-specific assay formulations achieving claimed accuracies of >95% to >99% against gold-standard LC-MS/MS comparators; no AI-native capabilities are disclosed beyond simple probability modeling in the HORMONElife app.

Wondfo USA firmographics

Firmographics
Name
Wondfo USA
Legal name
WONDFO USA CO., LTD.
Website
https://wondfousa.com
Company type
Private
Founded year
2009
Operating status
Operating
Headcount range
51–100 employees
Short description
Wondfo USA manufactures point-of-care rapid diagnostic tests — including COVID-19/Flu A&B multiplex, toxicology, harm reduction, women's fertility, and veterinary assays — serving consumers, healthcare providers, employers, and veterinarians across the US and Canada.
Ownership category
akta.pro rank

Where Wondfo USA is headquartered

Location

Headquarters

HQ city
Bolingbrook
HQ country
United States
HQ region
North America

Offices3 records

Markets served

Wondfo USA business model

Business model
GTM type
B2B and B2C
Offering type
Hardware or Manufacturing
Cost components
Supply Chain, Personnel, Technology or R&D, Marketing or Sales, Operations

Revenue model

  1. Rapid Diagnostic Test Products: One-time purchase model for point-of-care diagnostic test kits across infectious disease, toxicology, women's health, and veterinary categories. Revenue from product sales through direct channels, distributors, and retail partners.
  2. Instrument/Analyzer Sales: Sale of diagnostic instruments including PETlife Pro-DX Immunofluorescence Analyzer for veterinary diagnostics. No contract tie-in, pay-per-test model.

Pricing tiers

ModelBillingPrice
Unit PricingPay-as-you-goProduct pricing varies by product category and configuration

Go-to-market motion3 records

Distribution channels5 records

Marketing channels6 records

Wondfo USA product offering

Product offering

Core offering

Wondfo USA manufactures and distributes rapid point-of-care diagnostic test kits and benchtop analyzers across four divisions: WELLlife (infectious disease such as COVID-19, influenza A&B, strep A, fecal occult blood), SAFElife (drugs of abuse screening in urine, oral fluid, hair, and surface samples), HORMONElife and BABYlife (women's reproductive health strips), and PETlife (veterinary diagnostics run on the Pro-DX immunofluorescence analyzer). The company sells through direct sales, authorized distributors, retailers, and a Canadian distribution center to both professional healthcare customers and at-home consumers.

Product overview

Wondfo USA is a leading manufacturer of point-of-care rapid diagnostic tests organized into four main product sub-brands: WELLlife (infectious disease testing), SAFElife (toxicology/drug testing), HORMONElife/BABYlife (women's health and fertility), and PETlife (veterinary diagnostics). The WELLlife portfolio includes FDA 510(k) cleared and EUA-authorized COVID-19/Influenza A&B multiplex tests, standalone COVID-19 antigen tests, Flu A&B tests, iFOB fecal occult blood tests for colorectal cancer screening, and Strep A tests. SAFElife offers comprehensive toxicology solutions including multi-drug urine test cups and dip cards, oral fluid tests for cotinine and alcohol, hair follicle tests for long-term drug detection (90 days), and harm reduction test strips for fentanyl, xylazine, and benzodiazepines in liquid/powder samples. HORMONElife and BABYlife provide pregnancy tests, ovulation predictor kits, FSH tests, and a companion mobile app with predictive analytics for fertility tracking. PETlife features a portable immunofluorescence analyzer (Pro-DX) for canine progesterone, T4 thyroid, and pancreatic lipase testing, paired with the Pup Planner mobile app for breeders.

Differentiator

Problem solved

Functional benefit

Brands

  • WELLlife: Rapid point-of-care and OTC testing products for infectious diseases including COVID-19, influenza, and iFOB tests for health providers and consumers.
  • SAFElife
  • HORMONElife
  • PETlife
  • BABYlife

Products and services

  • WELLlife COVID-19 Antigen Test
  • WELLlife COVID-19 / Influenza A&B Antigen Test
  • WELLlife Influenza A&B Test
  • WELLlife iFOB Fecal Occult Blood Test
  • WELLlife Strep A Test
  • SAFElife Multi-Drug Urine Test Cup
  • SAFElife T-Dip Multi-Drug Urine Dip Card
  • SAFElife Fentanyl Urine Test
  • SAFElife T-Swab Cotinine and Alcohol Oral Fluid Test
  • SAFElife Hair Processor and Multi-Panel Rapid Hair Test
  • SAFElife Fentanyl Liquid and Powder Test Strip
  • SAFElife Xylazine Liquid and Powder Test Strip
  • SAFElife Benzodiazepines Liquid and Powder Test
  • HORMONElife Pregnancy Test
  • HORMONElife Ovulation Test Strip
  • HORMONElife PdG Urine Test Strip
  • HORMONElife Ultra Accurate FSH Test Strip
  • BABYlife Pregnancy Test
  • PETlife Pro-DX Immunofluorescence Analyzer

Quantifiable outcome

  • COVID-19 Antigen Test: Over 99% accuracy for negative tests, Over 84% accuracy for positive tests
  • +4 more outcomes

Companies that use Wondfo USA

Customer profile

Segments4 records

Ideal customer profiles4 records

Wondfo USA technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability2 records

Feature5 records

Wondfo USA partnerships and signals

Strategic signal

Partnerships

Four partnerships are on record, tiered core and minor.

  • DCN DxcoreStrategic or Co-development Partner · 16 May 2024Collaboration with DCN Dx, a leading contract research organization for in vitro diagnostics, through the NIH Rapid Acceleration of Diagnostics (RADx) Tech program for the development of WELLlife COVID-19/Influenza A&B test. DCN Dx provides research and validation services ensuring highest quality, accuracy, and reliability.
  • National Institutes of Health (NIH) RADx Tech ProgramcoreStrategic or Co-development Partner · 16 May 2024NIH RADx Tech program supporting rapid development and validation of COVID-19/Influenza diagnostic tests. Provides funding, expertise, and validation infrastructure for accelerated FDA clearance.
  • Fact.MRminorOthersMarket research firm providing industry analysis on pet at-home diagnostics market. Wondfo USA identified as one of 15-20 active players in market projected to reach USD 150.65 million by 2036.
  • Omega Laboratories, Inc.coreStrategic or Co-development PartnerComparative evaluation partner for SAFElife Multi-Panel Rapid Hair Test. Omega Laboratories conducted independent validation comparing Wondfo's hair test against their gold standard LC-MS/MS methodology.

Scale indicators5 records

Recent moves7 records

Expansion highlights6 records

Wondfo USA competitors and assessment

Company assessment

Broad incumbents

  • Abbott (Diagnostics): Global diagnostics leader with BinaxNOW rapid COVID/Flu and Strep tests, plus broader IVD and lab-testing franchises. Competes with Wondfo across rapid respiratory testing categories but at materially greater scale and brand recognition.
  • Becton, Dickinson and Company (BD): Operates the BD Veritor rapid-testing system for Flu, COVID and Strep A used in physician offices and urgent care, alongside women's health and drug-testing products. A broad incumbent overlapping directly with WELLlife and SAFElife.
  • IDEXX Laboratories: Global leader in veterinary diagnostics with in-clinic analyzers and rapid test kits for companion and livestock animals. Overlaps with Wondfo's PETlife Pro-DX analyzer at a much larger installed base, particularly in fertility, thyroid and pancreatic testing.
  • Zoetis: Largest pure-play animal health company with diagnostics, vaccines, and point-of-care vet testing. Competes with Wondfo PETlife in the broader vet diagnostics market but offers a much wider portfolio beyond diagnostics.

Direct peers

  • QuidelOrtho Corporation: Major US manufacturer of rapid IVD tests including COVID-19, Influenza A/B and Strep A assays used in both clinical point-of-care and OTC channels. Highly comparable product portfolio, channels, and regulatory posture to Wondfo's WELLlife line.
  • ACON Laboratories: US-headquartered rapid diagnostic manufacturer with lateral-flow COVID, Flu, pregnancy, fertility and drug-of-abuse tests sold OTC and to clinical channels. Closely comparable product mix and channel strategy to Wondfo across all four sub-brands.
  • BTNX Inc. Canadian rapid IVD manufacturer with strong HIV, pregnancy, drug-of-abuse and infectious disease lateral-flow products. Direct peer in both product categories and North American distribution footprint overlapping with Wondfo's Canadian channel.
  • SPD Swiss Precision Diagnostics (Clearblue): Global leader in home pregnancy and ovulation testing under the Clearblue brand, with connected fertility tracking. Directly comparable to Wondfo's HORMONElife/BABYlife lines at a much larger consumer brand scale.
  • Premier Biotech: US-based drug-testing and toxicology product manufacturer offering urine drug test cups, dip cards, oral fluid and saliva-based tests. Direct overlap with Wondfo's SAFElife multi-drug, fentanyl and harm-reduction product lines.
  • Princeton BioMeditech Corporation: Developer and manufacturer of rapid immunoassay tests for pregnancy, ovulation, drugs of abuse, infectious disease and cardiac markers. Closely comparable rapid-test product mix and lateral-flow technology base to Wondfo's HORMONElife, SAFElife and WELLlife lines.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks7 records

Key highlights7 records

Customer concentration

Wondfo USA social profiles

Digital presence

Wondfo USA compliance and trust

Trust signal

Compliance13 records

Wondfo USA financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Wondfo USA leadership team

Management profile

Number of profiles

Profiles2 records

Wondfo USA funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Wondfo USA M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Wondfo USA

What does Wondfo USA do?

Wondfo USA manufactures and distributes rapid point-of-care diagnostic test kits and benchtop analyzers across four divisions: WELLlife (infectious disease such as COVID-19, influenza A&B, strep A, fecal occult blood), SAFElife (drugs of abuse screening in urine, oral fluid, hair, and surface samples), HORMONElife and BABYlife (women's reproductive health strips), and PETlife (veterinary diagnostics run on the Pro-DX immunofluorescence analyzer). The company sells through direct sales, authorized distributors, retailers, and a Canadian distribution center to both professional healthcare customers and at-home consumers.

Is Wondfo USA a public or private company?

Wondfo USA is a private company. It is classified as unknown and is currently operating.

When was Wondfo USA founded?

Wondfo USA was founded in 2009. It employs 51 to 100 people.

Where is Wondfo USA based?

Wondfo USA is headquartered in Bolingbrook, United States, in the North America region.

How does Wondfo USA make money?

Two revenue lines are on record. Rapid Diagnostic Test Products are the primary driver. The others are instrument/Analyzer Sales.

Who are Wondfo USA's main competitors?

Broad incumbents on record are Abbott (Diagnostics), Becton, Dickinson and Company (BD), IDEXX Laboratories and Zoetis. Direct peers are QuidelOrtho Corporation, ACON Laboratories, BTNX Inc., SPD Swiss Precision Diagnostics (Clearblue), Premier Biotech and Princeton BioMeditech Corporation.

Does Wondfo USA have an API?

No public API is recorded for Wondfo USA.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals